NasdaqCM:LQDAPharmaceuticals
Rapid Uptake of YUTREPIA Might Change The Case For Investing In Liquidia (LQDA)
Liquidia Corporation recently highlighted strong early adoption of its YUTREPIA therapy for pulmonary arterial hypertension, with over 900 unique patient prescriptions written and more than 550 patient starts as of August 8, 2025.
This robust patient uptake led to increased revenue estimates for YUTREPIA for 2025 and 2026, well ahead of previous projections.
We’ll explore how accelerating YUTREPIA adoption is shaping expectations for Liquidia’s future growth and its overall investment...